Hospital
South Broward Hospital District
South Broward Hospital District was paid $22.75M by Medicaid between Jan 2018 and Dec 2024, across 298 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoSOUTH BROWARD HOSPITAL DISTRICT
PEMBROKE PINES, FL 33028
PEMBROKE PINES, FL 33028
33aNPI1134102080assigned 11/23/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.75M
24GClaims950,250
24DCodes billed298
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#10 of 163
Median peer was paid$4.77M
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 93,053 | $1.50M | |
| 2019 | 240,018 | $5.31M | |
| 2020 | 153,188 | $3.41M | |
| 2021 | 161,620 | $3.47M | |
| 2022 | 185,764 | $4.56M | |
| 2023 | 88,117 | $3.17M | |
| 2024incomplete | 28,490 | $1.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 41,614 | 35,180 | $3.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 38,318 | 34,549 | $3.21M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.4% | 17,879 | 16,691 | $1.69M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.8% | 25,409 | 4,934 | $1.32M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.5% | 10,232 | 2,310 | $787K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.7% | 6,194 | 5,727 | $622K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.4% | 9,344 | 2,194 | $550K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 3,744 | 3,158 | $520K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.3% | 10,548 | 8,426 | $512K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 7,863 | 6,067 | $471K |
| 80053 | Comprehensive metabolic panel | 2.0% | 30,489 | 19,371 | $464K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 5,905 | 4,686 | $446K |
286 more codes
| 96401 | 1.7% | 4,909 | $389K | |
| G0378 | Hospital observation service, per hour | 1.6% | 21,542 | $354K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.5% | 6,954 | $349K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 70,392 | $302K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 6,417 | $295K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 2,282 | $257K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,731 | $202K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,810 | $188K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,657 | $184K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 7,110 | $179K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,203 | $178K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,923 | $171K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,466 | $161K |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,639 | $161K |
| 86850 | <1% | 5,429 | $158K | |
| 96415 | <1% | 1,713 | $151K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 6,835 | $149K |
| 97113 | <1% | 1,009 | $139K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,819 | $134K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 35,661 | $126K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 150 | $121K |
| 87088 | <1% | 12,421 | $120K | |
| 76641 | <1% | 2,151 | $119K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,088 | $116K |
| 97162 | <1% | 1,849 | $116K | |
| 82962 | <1% | 14,901 | $107K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,810 | $104K |
| 96402 | <1% | 613 | $103K | |
| 84702 | <1% | 16,120 | $94K | |
| 36430 | <1% | 1,333 | $93K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,425 | $92K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,231 | $90K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,028 | $86K |
| 86900 | <1% | 6,439 | $83K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,899 | $83K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,824 | $76K |
| 97161 | <1% | 1,523 | $74K | |
| 87486 | <1% | 3,700 | $68K | |
| 87631 | <1% | 999 | $67K | |
| 96367 | <1% | 2,738 | $66K | |
| 85027 | <1% | 4,857 | $62K | |
| 96417 | <1% | 1,595 | $61K | |
| 84484 | <1% | 17,461 | $59K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,093 | $58K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,618 | $56K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,692 | $54K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,775 | $54K |
| 76770 | <1% | 1,046 | $51K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,067 | $50K |
| 83735 | <1% | 4,557 | $50K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 576 | $50K |
| 96377 | <1% | 68 | $49K | |
| 81001 | <1% | 21,291 | $48K | |
| 96411 | <1% | 337 | $48K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,285 | $48K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,871 | $46K |
| 97010 | <1% | 880 | $45K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 785 | $44K |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 520 | $43K |
| 77336 | <1% | 423 | $42K | |
| 86901 | <1% | 6,454 | $42K | |
| 81003 | <1% | 8,703 | $41K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,296 | $40K |
| 73610 | <1% | 975 | $39K | |
| 83615 | <1% | 2,731 | $38K | |
| 83880 | <1% | 1,830 | $35K | |
| 76801 | <1% | 2,801 | $34K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,271 | $34K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,366 | $33K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,710 | $33K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,490 | $32K |
| 86923 | <1% | 1,149 | $31K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,915 | $31K |
| 85610 | <1% | 11,456 | $31K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 149 | $31K |
| 93976 | <1% | 1,520 | $30K | |
| 84100 | <1% | 2,466 | $30K | |
| J9312 | Injection, rituximab, 10 mg | <1% | 72 | $30K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,969 | $28K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,234 | $28K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 593 | $27K |
| 81025 | <1% | 2,536 | $27K | |
| 70496 | <1% | 79 | $26K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,258 | $23K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 596 | $23K |
| 93970 | <1% | 982 | $23K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,025 | $22K |
| 82731 | <1% | 261 | $21K | |
| 92523 | <1% | 224 | $20K | |
| 85730 | <1% | 6,637 | $19K | |
| 87186 | <1% | 2,358 | $19K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 742 | $19K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,445 | $19K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,757 | $19K |
| 73130 | <1% | 582 | $19K | |
| 73562 | <1% | 1,415 | $18K | |
| 74021 | <1% | 820 | $18K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,046 | $18K |
| 82607 | <1% | 1,649 | $17K | |
| 86300 | <1% | 1,428 | $17K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,318 | $16K |
| 73080 | <1% | 204 | $16K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,456 | $16K |
| 73630 | <1% | 683 | $15K | |
| 82784 | <1% | 1,928 | $15K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,810 | $15K |
| 87581 | <1% | 3,694 | $14K | |
| 87040 | <1% | 5,597 | $14K | |
| 77066 | Tomosynthesis, mammo | <1% | 494 | $14K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 692 | $13K |
| 84112 | <1% | 301 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,084 | $13K |
| 80076 | <1% | 5,850 | $13K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 170 | $13K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,549 | $13K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,737 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,645 | $13K |
| 93971 | <1% | 1,111 | $12K | |
| 80061 | Lipid panel | <1% | 4,612 | $12K |
| 36592 | <1% | 623 | $12K | |
| 73110 | <1% | 380 | $12K | |
| 82378 | <1% | 1,771 | $12K | |
| 74019 | <1% | 1,434 | $12K | |
| 82728 | <1% | 1,989 | $12K | |
| 73030 | <1% | 810 | $11K | |
| 74018 | <1% | 799 | $11K | |
| 83690 | <1% | 8,853 | $10K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 456 | $10K |
| 86334 | <1% | 822 | $10K | |
| 83550 | <1% | 2,000 | $10K | |
| 83540 | <1% | 2,079 | $10K | |
| 71250 | <1% | 435 | $9K | |
| 96523 | <1% | 599 | $9K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 426 | $8K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 109 | $8K |
| 82746 | <1% | 1,290 | $7K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,696 | $7K |
| 85379 | <1% | 3,134 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,394 | $6K |
| 77080 | <1% | 231 | $6K | |
| 87210 | <1% | 1,856 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,430 | $6K |
| 73140 | <1% | 141 | $6K | |
| 86140 | <1% | 2,753 | $5K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 49 | $5K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 503 | $5K |
| 88342 | <1% | 622 | $5K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 159 | $5K |
| 87507 | <1% | 348 | $5K | |
| 87077 | <1% | 2,751 | $5K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 392 | $4K |
| 92526 | <1% | 174 | $4K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 480 | $4K |
| 82272 | <1% | 309 | $4K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 387 | $4K |
| 83883 | <1% | 957 | $4K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 342 | $4K |
| 83605 | <1% | 2,633 | $4K | |
| 72100 | <1% | 600 | $4K | |
| 84550 | <1% | 1,508 | $4K | |
| 84165 | <1% | 973 | $4K | |
| 73590 | <1% | 73 | $3K | |
| 70486 | <1% | 40 | $3K | |
| 87340 | <1% | 362 | $3K | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 5,757 | $3K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,997 | $3K |
| 84439 | <1% | 1,610 | $3K | |
| 82550 | <1% | 1,335 | $3K | |
| C1769 | Guide wire | <1% | 68 | $3K |
| 88341 | <1% | 106 | $3K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 74 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,301 | $2K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 825 | $2K |
| 73090 | <1% | 145 | $2K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 95 | $2K |
| 70544 | <1% | 76 | $2K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 248 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,316 | $2K |
| 86403 | <1% | 194 | $2K | |
| 84132 | <1% | 353 | $2K | |
| 73502 | <1% | 213 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,539 | $2K |
| 87070 | <1% | 631 | $2K | |
| 77072 | <1% | 24 | $1K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 53 | $1K |
| 82248 | <1% | 835 | $1K | |
| 94760 | <1% | 349 | $1K | |
| 72040 | <1% | 75 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 314 | $1K |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 179 | $1K |
| 97166 | <1% | 21 | $1K | |
| 77334 | <1% | 26 | $1K | |
| 82570 | <1% | 1,101 | $1K | |
| 12011 | <1% | 244 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 52 | $1K |
| 77062 | <1% | 146 | $1K | |
| 59025 | Fetal non-stress test | <1% | 61 | $920.31 |
| 85651 | <1% | 2,051 | $917.41 | |
| 10060 | <1% | 83 | $915.90 | |
| 97116 | <1% | 132 | $860.11 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 17 | $827.93 |
| 92610 | <1% | 18 | $811.11 | |
| 12001 | <1% | 82 | $787.64 | |
| 84156 | <1% | 308 | $701.73 | |
| 84153 | <1% | 64 | $700.40 | |
| 82805 | <1% | 75 | $685.95 | |
| 29125 | <1% | 167 | $663.22 | |
| 96376 | <1% | 289 | $635.81 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,773 | $623.55 |
| 77300 | <1% | 20 | $567.40 | |
| 87184 | <1% | 30 | $533.89 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 91 | $529.42 |
| 70547 | <1% | 13 | $491.40 | |
| 85014 | <1% | 193 | $478.53 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,925 | $453.25 |
| 85384 | <1% | 613 | $443.52 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 216 | $427.44 |
| 96368 | <1% | 49 | $421.54 | |
| 85045 | <1% | 539 | $393.85 | |
| 90715 | <1% | 286 | $370.52 | |
| 85018 | <1% | 192 | $346.18 | |
| 51701 | <1% | 1,074 | $333.84 | |
| 87205 | <1% | 430 | $332.45 | |
| 82247 | <1% | 26 | $324.91 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 122 | $311.03 |
| 87503 | <1% | 154 | $309.44 | |
| 94010 | <1% | 124 | $308.60 | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 24 | $289.51 |
| 82043 | <1% | 270 | $287.52 | |
| 86704 | <1% | 23 | $267.70 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 35 | $263.09 |
| 77001 | <1% | 13 | $262.47 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 83 | $259.42 |
| 78582 | <1% | 16 | $245.85 | |
| 87081 | <1% | 199 | $229.72 | |
| 82330 | <1% | 189 | $221.91 | |
| 97163 | <1% | 15 | $181.46 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 778 | $174.02 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 32 | $114.96 |
| 73620 | <1% | 28 | $106.25 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,275 | $92.72 |
| 82150 | <1% | 55 | $76.11 | |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | <1% | 31 | $75.00 |
| 76870 | <1% | 54 | $71.05 | |
| 88185 | <1% | 33 | $59.58 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 998 | $50.00 |
| 94618 | <1% | 17 | $33.43 | |
| 88184 | <1% | 17 | $29.80 | |
| 88304 | <1% | 170 | $16.95 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 46 | $11.68 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 44 | $5.50 |
| 3725F | 0% | 7,397 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 16 | $0.00 |
| 3078F | 0% | 782 | $0.00 | |
| 84145 | 0% | 80 | $0.00 | |
| 29515 | 0% | 116 | $0.00 | |
| 80179 | 0% | 46 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 266 | $0.00 |
| 1159F | 0% | 165 | $0.00 | |
| 80143 | 0% | 45 | $0.00 | |
| 1160F | 0% | 161 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 108 | $0.00 |
| 76000 | 0% | 16 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 51 | $0.00 |
| 36600 | 0% | 45 | $0.00 | |
| 84295 | 0% | 14 | $0.00 | |
| 93356 | 0% | 26 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 117 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 95 | $0.00 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 0% | 34 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 15 | $0.00 |
| 82140 | 0% | 23 | $0.00 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 13 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 6,423 | $0.00 |
| 3008F | 0% | 2,859 | $0.00 | |
| 1126F | 0% | 1,420 | $0.00 | |
| 1170F | 0% | 780 | $0.00 | |
| 3351F | 0% | 4,313 | $0.00 | |
| 3074F | 0% | 373 | $0.00 | |
| 29130 | 0% | 13 | $0.00 | |
| 1125F | 0% | 31 | $0.00 | |
| 3044F | 0% | 162 | $0.00 | |
| 86308 | 0% | 19 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 18 | $0.00 |
| 1111F | 0% | 21 | $0.00 | |
| J9070 | Cyclophosphamide, 100 mg | 0% | 47 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBURNS, MELISSA (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| South Broward Hospital District | Hollywood, FL | $81.73M |
| South Broward Hospital District | Pembroke Pines, FL | $14.98M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.